×
About 2,255 results

ALLMedicine™ Hereditary Angioedema Center

Research & Reviews  708 results

A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home
https://clinicaltrials.gov/ct2/show/NCT05489640

Aug 5th, 2022 - The main aim of this study is to describe the treatment patterns, characteristics and outcomes of people with HAE who are currently receiving icatibant in the homecare setting in the United Kingdom (UK). Participants will be treated with icatibant...

OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)
https://clinicaltrials.gov/ct2/show/NCT05139810

Aug 4th, 2022 - This is a Phase 3, multi-center, double-blind, randomized, placebo-controlled study of donidalorsen in up to 84 participants. Participants will be randomized in a 2:1 ratio to Cohort A (donidalorsen or placebo every 4 weeks) or Cohort B (donidalor...

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
https://clinicaltrials.gov/ct2/show/NCT05392114

Aug 4th, 2022 - This is a Phase 3, multi-center, open-label, global study with donidalorsen in up to approximately 114 participants with HAE-1 (Type I) and HAE-2 (Type II). There are two groups in this study: 1) participants who roll over from another study of do...

An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema
https://clinicaltrials.gov/ct2/show/NCT04307381

Aug 4th, 2022 - This is an open-label extension study of Donidalorsen in up to 24 participants with HAE. The length of participation in the study is approximately 68 weeks, which includes an up to 4-week qualification period, a 52-week treatment period, and a 12-...

CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks
https://clinicaltrials.gov/ct2/show/NCT04656418

Aug 3rd, 2022 - This is a multicenter, double-blind, randomized, placebo-controlled, parallel-arm study to investigate the efficacy and safety of subcutaneous administration of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema

see more →

Guidelines  4 results

The international WAO/EAACI guideline for the management of hereditary angioedema-The 2...
https://doi.org/10.1111/all.15214
Allergy Maurer M, Magerl M et. al.

Jan 11th, 2022 - Hereditary angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up-to-date guidanc...

The international WAO/EAACI guideline for the management of hereditary angioedema-The 2...
https://doi.org/10.1111/all.13384
Allergy Maurer M, Magerl M et. al.

Jan 11th, 2018 - Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. I...

A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, an...
https://doi.org/10.1016/j.jaci.2013.03.034
The Journal of Allergy and Clinical Immunology; Zuraw BL, Bernstein JA et. al.

Jun 4th, 2013 - These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council ...

International consensus and practical guidelines on the gynecologic and obstetric manag...
https://doi.org/10.1016/j.jaci.2011.11.025
The Journal of Allergy and Clinical Immunology; Caballero T, Farkas H et. al.

Dec 27th, 2011 - There are a limited number of publications on the management of gynecologic/obstetric events in female patients with hereditary angioedema caused by C1 inhibitor deficiency (HAE-C1-INH). We sought to elaborate guidelines for optimizing the managem...

see more →

Drugs  26 results see all →

Clinicaltrials.gov  101 results

A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home
https://clinicaltrials.gov/ct2/show/NCT05489640

Aug 5th, 2022 - The main aim of this study is to describe the treatment patterns, characteristics and outcomes of people with HAE who are currently receiving icatibant in the homecare setting in the United Kingdom (UK). Participants will be treated with icatibant...

OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)
https://clinicaltrials.gov/ct2/show/NCT05139810

Aug 4th, 2022 - This is a Phase 3, multi-center, double-blind, randomized, placebo-controlled study of donidalorsen in up to 84 participants. Participants will be randomized in a 2:1 ratio to Cohort A (donidalorsen or placebo every 4 weeks) or Cohort B (donidalor...

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
https://clinicaltrials.gov/ct2/show/NCT05392114

Aug 4th, 2022 - This is a Phase 3, multi-center, open-label, global study with donidalorsen in up to approximately 114 participants with HAE-1 (Type I) and HAE-2 (Type II). There are two groups in this study: 1) participants who roll over from another study of do...

An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema
https://clinicaltrials.gov/ct2/show/NCT04307381

Aug 4th, 2022 - This is an open-label extension study of Donidalorsen in up to 24 participants with HAE. The length of participation in the study is approximately 68 weeks, which includes an up to 4-week qualification period, a 52-week treatment period, and a 12-...

CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks
https://clinicaltrials.gov/ct2/show/NCT04656418

Aug 3rd, 2022 - This is a multicenter, double-blind, randomized, placebo-controlled, parallel-arm study to investigate the efficacy and safety of subcutaneous administration of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema

see more →

News  62 results

The Molting Man: Anasarca-Induced Full-Body Desquamation
https://www.mdedge.com/dermatology/article/253577/contact-dermatitis/molting-man-anasarca-induced-full-body-desquamation
Leon Kou, DO, Logan J. Kolb, DO et. al.

Apr 8th, 2022 - Edema blisters are a common but often underreported entity most commonly seen on the lower extremities in the setting of acute edema. 1 Reported risk factors and associations include chronic venous insufficiency, congestive heart failure, heredita.

New Drug Eliminates Most Angioedema Attacks in Early Test
https://www.medscape.com/viewarticle/970424

Mar 17th, 2022 - NEW YORK (Reuters Health) - Treatment with the experimental drug donidalorsen cut the number of attacks over 17 weeks by 90% in people with hereditary angioedema, according to the results from a 20-patient randomized phase-2 trial. The six placebo...

Momelotinib Trial Seeks to Address Myelofibrosis Symptoms
https://www.onclive.com/view/momelotinib-trial-seeks-to-address-myelofibrosis-symptoms

Oct 6th, 2021 - Momelotinib, an orally administered novel agent, is being evaluated in a phase 3 trial in patients with symptomatic and anemic myelofibrosis (MF), a population that experts say is in need of new options. The MOMENTUM trial (NCT04173494) will rando...

COVID-Clogged ICUs 'Terrify' Those With Chronic or Emergency Illness
https://www.medscape.com/viewarticle/957911

Aug 31st, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Jessica Gosnell, MD, 41, from Portland, Oregon, lives daily with the knowledge that her rare disease — a form of hereditary angioedema — could cau...

Berotralstat Reduces Hereditary Angioedema Attacks in Phase 3 Trial
https://www.medscape.com/viewarticle/956251

Aug 9th, 2021 - In late 2020, the US Food and Drug Administration (FDA) approved plasma kallikrein inhibitor berotralstat, making it the first oral, once-a-day treatment available for the prevention of hereditary angioedema (HAE) attacks in patients aged 12 years...

see more →

Patient Education  1 results see all →